This book covers lymphoproliferative disorders in patients with congenital or acquired immunodeficiencies. Acquired immunodeficiencies are caused by infections with the human immunodeficiency virus or arise following immunosuppressive therapy administered after organ transplantation or to treat connective tissue diseases such as rheumatoid arthritis. It was recently discovered that various diseases or therapeutic modalities that induce a state of immunosuppression may cause virally driven lymphoproliferations. This book summarizes for the first time this group of immunodeficiency-associated lymphoproliferations.

Immunosurveillance, Immunodeficiency and Lymphoproliferations

Clinicopathological Characteristics of Post-Transplant Lymphoproliferative Disorders
Latrogenic Lymphoproliferative Disorders in Non-Transplantation Settings
The Role of Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8) in Lymphoproliferative Diseases
Dendritic Cells for the Induction of EBV Immunity
NF-?B Inhibition in EBV-Transformed Lymphoblastoid Cell Lines
Epstein-Barr Viral Load as a Tool to Diagnose and Monitor Post-Transplant Lymphoproliferative Disease
The Role of Immunosuppression in Lymphoma
Indentification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders
Methods and Objectives of a Large US Multicenter Case-Control Study of Post-Transplant Lymphoproliferative Disorder in Renal Transplant Patients
Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations
Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease
Engineered Antibody for Treating Lymphoma
Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies
Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas
Non-Myeloablative Stem Cell Transplantation for Congenital Immunodeficiencies
Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma
Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma: Preliminary Results of a Phase I/II Study.